Day: September 18, 2025

SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 3rd China Great Bay Cell and Gene Therapy Forum, taking place in Guangzhou, China, September 25-26, 2025. Dr. Song will discuss the scientific rationale and recent clinical data supporting the use of the investigational autologous enhanced NK cell therapy, troculeucel, in the treatment of neurodegenerative diseases. This presentation underscores NKGen’s commitment to advancing innovative NK cell-based approaches in the rapidly evolving cell and...

Collaboration spans workers’ compensation, nursing homes, and outpatient clinics PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration between its U.S. subsidiary Nanox Impact Inc. and Monarch Medical Management and Billing LLC (“Monarch”), an experienced healthcare management organization with established relationships across industry sectors, to deploy Nanox’s advanced imaging solutions across multiple healthcare segments including workers’ compensation, nursing home facilities, and outpatient clinics. As part of the collaboration, Nanox will establish a comprehensive imaging network by deploying its technology across Monarch’s associated...

CALGARY, Alberta, Sept. 18, 2025 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT”, the “Company”, “we”, “our”, “us” or “ours”) (TSX: DRT; OTCQX: DRTTF), a leader in industrialized construction, today announced it will be participating at two upcoming investor conferences: the Smallcap Discoveries Conference in Vancouver and the Planet MicroCap Showcase in Toronto. Smallcap Discoveries Conference, VancouverDate: Monday, September 29, 2025DIRTT Environmental Solutions Presentation: 1:15 pm PTVenue: JW Marriott Parq, VancouverClick here to register: REGISTER Planet MicroCap Showcase, TorontoDate: Wednesday, October 22, 2025DIRTT Environmental Solutions Presentation: 3:00 pm ETVenue: Arcadian Court & Loft, TorontoClick here to register: REGISTER About DIRTT Environmental Solutions Ltd.DIRTT is a leader in industrialized...

Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CHATHAM, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the successful completion of a Type B Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of TNX-102 SL (sublingual cyclobenzaprine HCl) for the treatment of major depressive disorder (MDD). The Company received positive feedback from the FDA and plans to pursue a supplemental new drug application...

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0 million in incremental first lien term loans, and the upsize of its revolving credit facility from $170.3 million of maximum availability to $250.0 million of maximum availability. The combined $1.325 billion first lien term loans’ maturity dates were extended to 2032, and the revolving credit facility’s maturity date was extended from 2028 to 2030. Proceeds from the incremental first lien term loans were used to repay in full the existing second lien term loans in the amount of $415.0...

(Alta, Norway 18 September 2025) Statkraft has submitted a license application for an upgrade of the Alta power plant. By utilizing water currently bypassing the plant during floods, production could increase by up to 20 percent. This will be achieved by installing a third turbine, with minimal new environmental impact. The water flow in the salmon-carrying stretch of the Alta River will not be changed. When the Alta power plant was built in the 1980s, the facility was designed to accommodate three turbines. Due to grid limitations in Finnmark at the time, only two were installed. The turbine is a part of the installation that generates electricity from the energy in the water. Since the power grid has been reinforced in recent years, it can now handle more electricity. Statkraft is therefore applying for a license to increase power generation...

Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Improvement Amendments (CLIA) HOUSTON, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has received a certificate of accreditation from CMS for its lab located in Houston, Texas. Following the recent planned laboratory audit, successful certificate of accreditation deems the lab compliant with Clinical...

Award builds on recent momentum in ports & harbors RESTON, Va., Sept. 18, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, has been awarded a contract to provide planning and design services relating to the redevelopment of the West End Container Yard at Barbours Cut Terminal in the Port of Houston. The selection builds on more than $5 million in recent assignments involving major U.S. ports and private oil and gas terminal operators, including work in intermodal freight planning, cruise terminal development and marine infrastructure engineering. This marks the company’s first container terminal planning and design services award and expands its reach within the ports and harbors market. “Our commitment to increase our ports and harbors revenue...

Completed patient enrollment within nine months with nearly half enrolled from the U.S. Expect to report Phase 3 topline data in the first half of 2026 On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the first half of 2027 Plan to present additional data from the Phase 1/2 study in the fourth quarter of 2025CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE). Topline data are expected in the first half of 2026. Intellia is on track to submit a biologics license application (BLA)...